HP provides a cross-cutting policy perspective that bridges Departmental programs, public and private sector activities, and the research community, in order to develop, analyze, coordinate and provide leadership on health policy issues for the Secretary. HP carries out this mission by conducting policy, economic and budget analyses, assisting in the development and review of regulations, assisting in the development and formulation of budgets and legislation, assisting in survey design efforts, as well as conducting and coordinating research, evaluation, and information dissemination on issues relating to health policy.
The Office of Health Policy is organized in four divisions that align with major Department programs :Division of Health Care Financing Policy (HFP)
Division of Public Health Services (PHS)
Division of Health Care Access and Coverage (HAC)
Division of Health Care Quality and Outcomes (HQO)
HEALTH POLICY RESEARCH:
- Reports to Congress
- Affordable Care Act Research & Issue Briefs
- HP Authored or Sponsored Work Published in Journals
OTHER HELPFUL INFORMATION:
- Children's Health Insurance and CHIP
- Consumer Protection and Patient Safety
- Health Information and Statistics
- Health Policy
- Health Promotion and Disease Prevention
- Health Insurance Marketplace
- Healthcare Reform
- Other Research
- Patient-Centered Outcomes Research Trust Fund (PCORTF)
- Public Health
- Healthcare Safety Net
- Substance Abuse and Mental Health
The American Rescue Plan (ARP) enhances and expands eligibility for advance payments of premium tax credits (APTCs) to purchase Marketplace insurance coverage under the Affordable Care Act (ACA).
This report represents a landscape review of community-level efforts to address SDOH, followed by interviews with participants in three community-level initiatives that have built networks to coordinate clinical and social services.
Many uninsured individuals can access zero-premium or low-premium health plans after application of premium tax credits under the Affordable Care Act.
The Affordable Care Act (ACA), signed into law on March 23, 2010, extended health coverage to millions of Americans through Medicaid (in the states participating in Medicaid expansion) and subsidized Marketplace coverage.
Experience during the first six months of the pandemic shows that the risks of Medicare fee-for-service (FFS) beneficiaries contracting COVID-19 and subsequent hospitalization and mortality vary significantly by demographic characteristics, health status, and nursing home residence.
Health Disparities by Race and Ethnicity during the COVID-19 Pandemic: Current Evidence and Policy Approaches
The COVID-19 pandemic has highlighted stark health disparities among Black, Hispanic, Native American, and Native Hawaiian/Pacific Islander populations in several areas, including infections, hospitalizations, death rates, and vaccination rates.
State, County, and Local Estimates of the Uninsured Population: Prevalence and Key Demographic Features
ASPE has developed state and sub-state estimates of the number of uninsured, along with their demographic characteristics, who are likely to qualify for coverage through Qualified Health Plans (QHPs) in the Health Insurance Marketplace (“QHP-eligible uninsured”) using the most recent Census data available for this purpose.
This issue brief examines the effects on coverage and access to care of policies in four major areas of state Medicaid section 1115 demonstrations
Permanency, that is ensuring children have long-term, enduring connections to family or other caring adults, is one of the three primary goals of the child welfare system, along with safety and child well-being.
Newly released estimates from the National Health Interview Survey show that 11.1 percent of U.S. residents (or 30.0 million) under age 65 lacked health insurance as of January-June 2020.
The United States relies on the interactions of private entities – drug manufacturers, health plans and pharmaceutical benefit managers (PBMs) - to achieve value by negotiating prices, operating formularies and implementing other benefit management strategies.
This brief explores lessons about six strategies federal or philanthropic agencies can take to try to enhance local cross-sector collaboration.
Market-based payment policies such as competitive bidding, reference pricing, centers of excellence and tiered provider networks have been implemented both in Medicare and across the private sector, as described in this report required by Executive Order 13890.
This project report provides potential approaches to expand and strengthen the entry-level health care workforce in the United States.
Medicare covers prescription drugs provided during inpatient hospital and skilled nursing facility stays through Part A, retail prescription drugs through Part D, and drugs provided in physicians’ offices and hospital outpatient departments through Part B.
The September 13, 2020 Executive Order on Lowering Drug Prices by Putting America First declared, “It is the policy of the United States that the Medicare program should not pay more for costly Part B or Part D prescription drugs or biological products than the most-favored-nation price.”
Beginning in mid-March 2020, the COVID-19 pandemic has had an unprecedented impact on health care utilization. The impact on patients, their families and the health care system was significant.
This report describes progress HHS has made over the past year to implement the Department’s Advancing American Kidney Health (AAKH) initiative and the Executive Order that accompanied the initiative. The AAKH initiative, which was launched in July 2019, outlined specific action steps to transform kidney care by focusing on three goals: reducing the risk of kidney failure, improving access to and quality of person-centered treatment options, and increasing access to kidney transplants. Related Products:
This report responds to a requirement in Executive Order 13877, "Improving Price and Quality Transparency in American Healthcare to Put Patients First." It describes the phenomenon of a "surprise billing," particularly in the commercial insurance market, the underlying federal and state regulatory frameworks, and recent state actions to address the problem. It also describes federal actions to encourage price transparency for medical services.
ASPE Issue Brief: Medicare Beneficiary Use of Telehealth Visits: Early Data From the Start of the COVID-19 Pandemic
This ASPE issue brief examines changes in Medicare fee-for-service primary care visits and use of telehealth at the start of the COVID-19 public health emergency (PHE). This brief seeks to address the issue of how and whether the Medicare telehealth flexibilities introduced to address the COVID-19 pandemic may have helped maintain access to primary health care during the PHE. Data reflects visits up to early June in 2020.
Parental opioid use disorder (OUD) is a risk factor for the maltreatment of children and placement into foster care. Opioid agonist therapy (OAT) is an evidence-based treatment for OUD using medications such as methadone and buprenorphine. OAT can help parents enter recovery and reduce the risk of maltreatment, and potentially improve child welfare outcomes. Child welfare agencies are increasingly looking to connect parents with treatment. However, there are concerns of inadequate supply of OAT providers.
This brief analyzes information on administrative data resources collected by the Administration for Children and Families (ACF). It explores how the data can be leveraged to improve evidence and research on ACF programs and beneficiaries. Key highlights include:
The Secretary of Health and Human Services (HHS) has been directed to submit a drug pricing report containing information requested by the House Committee on Appropriations. In response, the Assistant Secretary for Planning and Evaluation (ASPE) developed this report containing data and analyses related to prescription drug spending between 2006 and 2017 as well as on prescription drugs benefiting from public funding for biomedical research since 2013
This Report responded to a request from the House and Senate Committees on Appropriations. Published estimates of the cost of new drug development range from $1.2 billion to $2.6 billion and are highly sensitive to assumptions about pre-clinical and clinical development time, cost of capital, the likelihood of reaching approval following the start of clinical testing, and costs of preclinical development and clinical trials conducted among humans, and to the incorporation of recent increases in Orphan drug approvals.